NuCana (NCNA) shares soared 164% amid heavy trading after the company said Saturday that a combination of NUC-7738 and pembrolizumab led to prolonged progression-free survival in a phase 2 trial for patients with metastatic melanoma.
More than 50.1 million shares traded intraday compared with a daily average of about 138,000.
Nuvalent (NUVL) said Saturday that data from the ongoing parallel phase 1/2 trials of zidesamtinib and NVL-655 to treat non-small cell lung cancer showed "favorable tolerability."
Shares climbed 23%, with intraday trading volume at over 1.9 million compared with a daily average of about 344,000.
Zentalis Pharmaceuticals (ZNTL) said the US Food and Drug Administration lifted a partial clinical hold on studies of azenosertib, the company's novel and orally bioavailable inhibitor for advanced solid tumors.
Shares advanced 20% as intraday trading volume rose to 41.4 million versus the stock's daily average of about 1.49 million.
Price: 6.71, Change: +4.17, Percent Change: +164.09
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。